Soluble TREM-1 ameliorates gouty arthritis by selective inhibition of proinflammatory cytokines and chemokines without affecting TGFβ production.
TREM-1 blockade (LP17) in gouty arthritis selectively inhibits proinflammatory cytokines and chemokines, whereas the level of TGF β remains unaffected. Thus, LP17 induces a shift towards anti-inflammatory cytokine TGFβ that results in spontaneous resolution of the gout attack.
Authors
- Irina Lagovsky
- Yair Molad (ORCID: https://orcid.org/0000-0003-0630-8762)
Institutions
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2024-10-09
- DOI
- https://doi.org/10.55563/clinexprheumatol/jv9d10
- Primary Topic
- Inflammation biomarkers and pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00